Amyrt's AP103 Receives the US FDA's Orphan Drug designation for Dystrophic Epidermolysis Bullosa (DEB)
Shots:
- The US FDA has granted orphan drug designation for AP103 for the treatment of DEB
- Amyrt licensed a pre-clinical gene – therapy platform technology to treat patients with DEB- a subset of EB also applicable for genetic disorders in Mar 2018
- AP103 is based on a novel polymer-based topical delivery platform and offers potential advantages in the gene therapy field also used in other genetic skin conditions
Ref: GlobeNewswire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
